CK 101

Drug Profile

CK 101

Alternative Names: CK-101; Covalent 3rd generation EGFR inhibitors - Fortress Biotech/NeuPharma; Irreversible third generation EGFR inhibitors - Fortress Biotech/NeuPharma; RX-518

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suzhou NeuPharma
  • Developer Checkpoint Therapeutics
  • Class Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 11 Sep 2017 CK 101 receives Orphan Drug status for Non-small cell lung cancer in USA
  • 01 Apr 2017 Interim pharmacodynamic data from preclinical study in Non small cell lung cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 17 Mar 2017 Checkpoint Therapeutics has patents pending CK 101 and related compounds, in Canada, Europe, USA and World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top